Applicability of Non‐Invasive Eligibility Criteria for MASH Pharmacotherapy: A Multicentre Cohort Study
Liver International · 2026
DOI: 10.1111/liv.70882 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, 2026. Verfasst von Nicola Pugliese und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. Hauptthemen laut MEDLINE: Fatty Liver, Liver, Non-alcoholic Fatty Liver Disease, Patient Selection. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Background and Aims Non‐invasive tests (NITs) are increasingly used to guide patient selection for pharmacological treatment of metabolic dysfunction‐associated steatohepatitis (MASH). We aimed to quantify and compare real‐world treatment eligibility according to the AASLD and expert panel‐derived criteria and to evaluate classification of patients with available liver histology.
Methods
We retrospectively included 897 adults with MASLD from four Italian referral centres. Eligibility was assessed using AASLD criteria, defined by liver stiffness measurement (LSM) 8–15 kPa without cirrhosis, and expert panel‐derived criteria, defined by LSM 10–19.9 kPa, platelet count ≥ 140 × 10 9 /L, and no cirrhosis. A subgroup of 175 patients underwent liver biopsy within ±3 months of first referral.
Results
Median age was 62 years, 57.1% were men, 48.4% had obesity, and 36.0% had Type 2 diabetes. Overall, 202 patients (22.5%) met AASLD criteria and 114 (12.7%) met expert panel‐derived criteria. Eighty‐six patients were eligible according to both criteria, whereas 144 were classified differently. Type 2 diabetes and obesity were independently associated with eligibility under both criteria. In the biopsy subgroup, 73 patients had histological F2–F3 fibrosis; 35 (47.9%) did not meet AASLD criteria and 49 (67.1%) did not meet expert panel‐derived criteria.
Conclusions
The AASLD and expert panel‐derived criteria identified different real‐world populations potentially suitable for MASH pharmacotherapy. In the biopsy subgroup, NIT‐based eligibility classification only partly aligned with histological F2–F3 fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
- Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Italy.
- Hepatology Unit, San Giuseppe Hospital, Milan, Italy.
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
- Section of Gastroenterology, PROMISE, University of Palermo, Palermo, Italy.
- Unit of Metabolic Disease, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
ORCID-Profile: Nicola Pugliese, Arianna Bertazzoni, Federica Cerini, Grazia Pennisi, Rosa Lombardi, Valerio Gullace, Mauro Viganò, Salvatore Petta, Alessio Aghemo
Zitieren
APA
Pugliese, N., Polverini, D., Bertazzoni, A., Cerini, F., Pennisi, G., Lombardi, R., Gullace, V., De Nicola, S., Masetti, C., Paviglianiti, A., Fracanzani, A. L., Viganò, M., Petta, S., & Aghemo, A. (2026). Applicability of Non‐Invasive Eligibility Criteria for MASH Pharmacotherapy: A Multicentre Cohort Study. Liver International. https://doi.org/10.1111/liv.70882
Vancouver
Pugliese N, Polverini D, Bertazzoni A, Cerini F, Pennisi G, Lombardi R, et al. Applicability of Non‐Invasive Eligibility Criteria for MASH Pharmacotherapy: A Multicentre Cohort Study. Liver International. 2026. doi:10.1111/liv.70882
BibTeX
@article{Pugliese2026,
author = {Pugliese, Nicola and Polverini, Davide and Bertazzoni, Arianna and Cerini, Federica and Pennisi, Grazia and Lombardi, Rosa and Gullace, Valerio and De Nicola, Stella and Masetti, Chiara and Paviglianiti, Andrea and Fracanzani, Anna Ludovica and Viganò, Mauro and Petta, Salvatore and Aghemo, Alessio},
title = {Applicability of Non‐Invasive Eligibility Criteria for MASH Pharmacotherapy: A Multicentre Cohort Study},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70882}
}
EUVIMED